WeVote
Log In

Bill

Bill

S 3325

Expanding Access to Affordable Drugs and Medical Devices Act

119th Congress Introduced by John Curtis and 1 co-sponsor

Senate bill expanding drug and device access through competitive measures and price negotiation to improve healthcare affordability for American consumers.

Introduced in Senate
1
WeVote Research Nonpartisan
Bill Summary · S 3325

Legislative bill overview

S 3325 aims to expand access to affordable drugs and medical devices through mechanisms that would likely increase competition and potentially allow importation or price negotiation. The bill was introduced in December 2025 and is currently under review by the Senate Finance Committee, which oversees healthcare and pharmaceutical policy.

Why is this important

Drug and medical device affordability is a persistent policy challenge affecting millions of Americans who delay or skip medications due to cost. This bill directly addresses healthcare accessibility, which has significant implications for public health outcomes, healthcare system costs, and pharmaceutical industry operations.

Potential points of contention

  • Price controls vs. innovation concerns: Proposals to lower drug prices face opposition from pharmaceutical manufacturers who argue price constraints reduce incentives for research and development of new treatments
  • International trade implications: Drug importation mechanisms may conflict with trade agreements and intellectual property protections that pharmaceutical companies rely on
  • Market structure effects: Increased competition measures could reshape relationships between manufacturers, insurers, pharmacy benefit managers, and healthcare providers in ways that benefit some stakeholders while harming others

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.